Overriding imatinib resistance with a novel ABL kinase inhibitor

Science

Volumn 305, Issue 5682, 2004, Pages 399-401

  Shah, Neil P ^a   Tran, Chris ^a,b   Lee, Francis Y ^c   Chen, Ping ^c   Norris, Derek ^c   Sawyers, Charles L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE; CRYSTALLOGRAPHY; PATIENT TREATMENT;

BONE MARROW; CHRONIC MYELOID LEUKEMIA (CML); MUTATIONS; PROGENITORS;

DISEASES;

ABELSON KINASE; ABELSON KINASE INHIBITOR; BCR ABL PROTEIN; DASATINIB; ENZYME INHIBITOR; IMATINIB; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

MEDICINE;

ARTICLE; BONE MARROW CELL; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; STEM CELL; TUMOR CELL CULTURE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL DIVISION; CELL LINE; CLINICAL TRIALS, PHASE I; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MICE; MICE, SCID; MUTATION; PIPERAZINES; PROTEIN CONFORMATION; PYRIMIDINES; THIAZOLES; TRANSFECTION;

EID: 3142676436     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1099480     Document Type: Article

References (24)

1. B. J. Druker et al., N. Engl. J. Med. 344, 1031 (2001).
2. S. G. O'Brien et al., N. Engl. J. Med. 348, 994 (2003).
3. M. E. Gorre et al., Science 293, 876 (2001).
4. T. Schindler et al., Science 289, 1938 (2000).
5. B. Nagar et al., Cancer Res. 62, 4236 (2002).
6. N. von Bubnoff, F. Schneller, C. Peschel, J. Duyster, Lancet 359, 487 (2002).
7. S. Branford et al., Blood 99, 3472 (2002).
8. C. Roche-Lestienne et al., Blood 100, 1014 (2002).
9. N. P. Shah et al., Cancer Cell 2, 117 (2002).
10. A. Hochhaus et al., Leukemia 16, 2190 (2002).
11. H. K. Al-Ali et al., Hematol. J. 5, 55 (2004).
12. P. La Rosee, A. S. Corbin, E. P. Stoffregen, M. W. Deininger, B. J. Druker, Cancer Res. 62, 7149 (2002).
13. D. R. Huron et al., Clin. Cancer Res. 9, 1267 (2003).
14. L. J. Lombardo et al., in preparation.
15. Materials and methods are available as supporting material on Science Online.
16. M. Azam, R. R. Latek, G. Q. Daley, Cell 112, 831 (2003).
17. M. Deng, G. Q. Daley, Blood 97, 3491 (2001).
18. T. Oda et al., J. Biol. Chem. 269, 22925 (1994).
19. N. P. Shah et al., unpublished data.
20. B. J. Druker et al., Nature Med. 2, 561 (1996).
21. M. Warmuth et al., Blood 101, 664 (2003).
22. J. Cools et al., N. Engl. J. Med. 348, 1201 (2003).
23. K. Shah, Y. Liu, C. Deirmengian, K. M. Shokat, Proc. Natl. Acad. Sci. U.S.A. 94, 3565 (1997).
24. We thank M. Lynch for assistance with CFU assays, J. Nicoll for technical assistance, and B. Katz for assistance with preparation of the manuscript. Supported by a Career Development Award for Fellows (N.P.S.) and a Specialized Center of Research Program Grant from the Leukemia & Lymphoma Society, an NIH K12 Mentored. Clinical Scholars Research Program in Clinical Pharmacology (N.P.S.), and a Doris Duke Charitable Foundation Distinguished Clinical Scientist Award (C.L.S.).